title: Preparation and characterization of ofloxacin microspheres for the eradication of bone associated bacterial biofilm.
abstract: Biodegradable polymers for localized delivery of antibiotics have emerged as an important approach to treating orthopaedic infections. In chronic forms of osteomyelitis which are thought to be associated with bacterial biofilm, localized delivery of a suitable antibiotic is desirable. This paper describes the formulation and in vitro evaluation of biodegradable ofloxacin microspheres for the eradication of bone associated bacterial biofilm infections. Ofloxacin microspheres were formulated using poly(glycolic acid-co-DL-lactic acid) (PGLA) by the emulsion solvent evaporation technique. The effects of process parameters such as phase volume, poly(vinyl alcohol) (PVA) concentration, and viscosity grade of the polymer during preparation on encapsulation efficiency (EEF) and in vitro release profiles were investigated. An increase in the phase volume or volume fraction from 21 to 35% at a constant internal phase volume resulted in an increase in EEF from 34 to 74%. Increasing PVA concentration from 0.25 to 2.5% w/v at a constant phase volume or volume fraction did not have an effect on the EEF. Ofloxacin release from the microsopheres was biphasic with an initial burst release followed by a slow release phase. An optimum slowing down of release was observed when the phase volume was 29%. Above and below this phase volume, release of ofloxacin was higher. The higher the viscosity grade of the polymer used for the preparation of microspheres, the higher the PVA concentration needed to prepare microspheres with slower release. The study indicates that various rates of ofloxacin release is possible by varying formulation conditions. This should provide a means for formulating sustained release microspheres of antibiotics for the treatment of biofilm infections associated with the bone.
authors.affiliation: College of Pharmacy and Pharmaceutical Sciences, Howard University, Washington, D.C. 20059, USA.
authors.forename: M
authors.initials: M
authors.lastname: Habib
authors.forename: S
authors.initials: S
authors.lastname: Onyilofor
authors.forename: N K
authors.initials: NK
authors.lastname: Ebube
authors.forename: G
authors.initials: G
authors.lastname: Owusu-Ababio
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000737:chemistry*; D023181:Antimicrobial Cationic Peptides; D001673:Biodegradation, Environmental; D018441:Biofilms / Q000187:drug effects*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003692:Delayed-Action Preparations; D008863:Microspheres; D015242:Ofloxacin / Q000008:administration & dosage / Q000737:chemistry*; D010019:Osteomyelitis / Q000188:drug therapy / Q000382:microbiology; D010455:Peptides / Q000737:chemistry*; D011142:Polyvinyl Alcohol / Q000737:chemistry*